Spanish pharmaceutical firm Almirall forecast on Monday a drop in core earnings this year after a 15.8% decline in 2022 due to increased investment in research and development, as well as lower sales in the United States.
https://www.pharmalive.com/wp-content/uploads/2023/02/ReutersAlmirall2-20-2023.jpg8291200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-20 05:07:372023-02-20 09:52:35Spain's Almirall expects core earnings to fall in 2023
